Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS

Journal of Neuropathology and Experimental Neurology

Volumn 55, Issue 12, 1996, Pages 1259-1269

  Lasner, Todd M ^a,b   Kesari, Santosh ^b,c   Brown, S Moira ^d   Lee, Virginia M Y ^c   Fraser, Nigel W ^b   Trojanowski, John Q ^c,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INSTITUTE OF VIROLOGY   (United Kingdom)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Brain tumor therapy; Herpes simplex virus; ICP34.5; Medulloblastoma; Nude mouse; Pediatrics

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEDULLOBLASTOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0029906853     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199612000-00010     Document Type: Article

References (45)

1. Kramer S, Meadows AT, Jarrett P. Incidence of childhood cancer: Experience of a decade in a population-based registry. J Natl Cancer Inst 1983;70:49-55
2. Silverberg E, Lubera JA. Cancer statistics. Cancer Res 1986;36: 4-23
3. Geyer JR, Berger M. Central nervous system malignancies in children. NY State J Med 1990;90:601-8
4. Rorke LB. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 1983;42:1-15
5. Mori K, Kurisaka M. Brain tumors in childhood: Statistical analysis of cases from the Brain Tumor Registry of Japan. Childs Nerv Syst 1986;2(5):233-37
6. Lannering B, Marky I, Nordburg C. Brain tumors in childhood and adolescence in west Sweeden 1970-1984. Epidemiology and survival. Cancer 1990;66(3):604-9
7. Yachnis AT, Rorke LB, Trojanowski JQ. Cerebellar dysplasias in humans: Development and possible relationship to glial and primitive neuroectodermal tumors of the cerebellar vermis. J Neuropathol Exp Neurol 1994;53(1):61-71
8. Fung K-M, Trojanowski JQ. Animal models of medulloblastomas and related primitive neuroectodermal tumors. A review. J Neuropathol Exp Neurol 1995;54(3):285-96
9. Tohyama T, Lee VM-Y, Rorke LB, Marvin M, McKay RDG, Trojanowski JQ. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest 1992;66(3):303-13
10. Lefkowitz IB, Packer RJ, Ryan SG, et al. Late recurrence of primitive neuroectodermal tumor/medulloblastoma. Cancer 1988;62(4):826-30
11. Tarbell NJ, Loeffler JS, Silver B, et al. The change in patterns of relapse in medulloblastoma. Cancer 1991;68(7):1600-1604
12. Deutsch M. Medulloblastoma. Staging and treatment outcome. International J Rad Onc Bio Physics 1988;14(6):1103-7
13. MacLean AR, Brown SM. Generation of a herpes simplex virus type 1 variant devoid of Xbal sties. J Gen Virol 1987;68: 1165-71
14. MacLean AR, Ul-Fareed M, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991;72:631-39
15. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant glioraas. Nature Med 1995;1(9):938-43
16. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human malignant glioma by means of a genetically engineered virus mutant. Science 1991;252(5007):854-56
17. Marken JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993;32:597-603
18. Kesari S, Randazzo BP, Vali-Nagy T, et al. Therapy of experimental brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995;73(5):636-48
19. Corey L, Spear PG. Infections with herpes simplex viruses. (First of two parts). New Engl J Med 1986;314:686-91
20. Corey L, Spear PG. Infections with herpes simplex viruses. (Second of two parts). New Engl J Med 1986;314:749-57
21. Fraser NW, Block TM, Spivack JG. The latency-associated transcripts of herpes simplex virus: RNA in search of function. Virology 1992;191:1-8
22. Ackermann M, Longnecker R, Roizman B, Pereira L. Identification, properties, and gene location of a novel glycoprotein specified by herpes simplex virus 1. Virology 1986;150:207-20
23. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 1 34.5, a gene nonessential for growth in culture. Science 1990;250:1262-66
24. McGeoch DJ, Cunningham C, McIntyre G, Dolan A. Comparative sequence analysis of the long repeat regions and adjoining parts of the long unique regions in the genomes of herpes simplex viruses types 1 and 2. J Gen Virol 1991;72:3057-75
25. Taha MY, Brown SM, Clements GB, Graham DI. The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice. J Gen Virol 1990;71:1597-1601
26. Chambers R, Gillespie GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci 1995;92:1411-15
27. Brown SM, Harland J, MacLean AR, Podlech J, Clements JB. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J Gen Virol 1994;75:2367-77
28. Bolovan CA, Sawtell NM, Thompson RL. ICP 34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol 1994;68:48-55
29. Chou J, Roizman B. The γ34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA 1992;89(8):3266-70
30. Chou J, Chen J-J, Gross M, Roizman B. Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF2α and premature shutoff of protein synthesis after infection with γ134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995;92:10516-20
31. Valyi-Nagy T, Fareed MU, O'Keefe JS, et al. The HSV-1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 1994;75:2059-63
32. Friedman HS, Burger PC, Bigner SH, et al. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol 1985;44(6): 592-605
33. Spivack JG, Fraser NW. Detection of herpes simplex type 1 transcripts during latent infection in mice. J Virol 1987;61:3841-47
34. Valyi-Nagy T, Deshmane SL, Raengsakulrach B, et al. Herpes simplex virus type 1 mutant strain in 1814 establishes a unique, slowly progressing infection in SCID mice. J Virol 1992;66:7336-45
35. Holland TC, Marlin SD, Levine, M Glorioso J. Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies. J Virol 1983;45:672-82
36. Muggeridge MI, Wilcox WC, Cohen GH, Eisenberg RJ. Identification of a site on herpes simplex virus type 1 glycoprotein D that is essential for infectivity. J Virol 1990;64:3617-26
37. Hung S-L, Srinivasan S, Friedman HM, Eisenberg RJ, Cohen GH. The structural basis of C3b binding by glycoprotein C of Herpes Simplex Virus. J Virol 1992;66(7):4013-27
38. Trojanowski JQ, Mantione JR, Lee JH, et al. Neurons derived from a human teratocarcinoma cell line establishes molecular and structural polarity following transplantation into the rodent brain. Experimental Neurology 1993;122:283-94
39. Trojanowski JQ, Fung K-M, Rorke LB, Tohyama T, Yachnis AT, Lee VM-Y. In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood. Mol Chem Neuropath 1994;21(2-3):219-39
40. Deatly AM, Spivack JG, Lavi E, O'Boyle DR2, Fraser NW. Latent herpes simplex virus type 1 transcripts in peripheral and central nervous system tissues of mice map to similar regions of the viral genome. J Virol 1988;62:749-56
41. Kesari S, Lee VM-Y, Brown SM, Trojanowski JQ, Fraser NW. Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. J Neurosci 1996;16:5644-53
42. Valyi-Nagy T, Deshmane SL, Spivack JG, et al. Investigation of herpes simplex virus type 1 (HSV-1) gene expression and DNA synthesis during the establishment of latent infection by an HSV-1 variant, in1814, that does not replicate in mouse trigeminal ganglia. J Gen Virol 1991;72:641-49
43. Adams RL, Springall DR, Levene MM, Bushell TE. The immunocytochemical detection of herpes simplex virus in cervical smears - a valuable technique for routine use. J Pathol 1984;143(4): 241-47
44. Randazzo BP, Kesari S, Gesser RM, et al. Treatment of experimental intracranial murine melanoma with a neuro-attenuated herpes simpex virus-1 mutant. Virol 1995;211(1):94-101
45. Boviatis EJ, Scharf JM, Chase M, et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy 1994;1:323-31